Lightnews — Scholar-powered news

Federica Fogacci @federicafogacci.bsky.social · 10d

Happening Today – Don’t Miss It!
Join the @eassociety.bsky.social webinar at 17:00 CET to explore the latest Lp(a) guidelines with Dr. Koskinas and Prof. @LaleTokgozoglu. Bring your questions and join the live Q&A—we can’t wait to connect with you online 💫
Rego: eas.to/WebSep29Reg
#EASSoMe #CvPrev

Welcome! You are invited to join a webinar: EAS/ESC Guidelines: Lipoprotein(a) – guideline updates and clinical case. After registering, you will receive a confirmation email about joining the webinar...

Join us for an insightful webinar exploring the latest Lipoprotein(a)-related guideline recommendations. The session will feature a 20-minute overview presentation by Dr Konstantinos Koskinas, followe...

eas.to

1 1

Federica Fogacci @federicafogacci.bsky.social · 11d

Feeling honored to be recognized for the 3rd consecutive year on Stanford University and Elsevier’s Top 2% Scientists list. #Grateful to my incredible colleagues and mentors — thank you for your support as we keep pushing boundaries and growing together @unibo.it @eassociety.bsky.social #CvPrev

1 2

Federica Fogacci @federicafogacci.bsky.social · Jul 24

Super excited to be selected for the first IAS Inflammation Academy 🌟
Looking forward to learning, sharing ideas, and being inspired by amazing mentors and peers #CvPrev
#EASSoMe @eassociety.bsky.social
🔗https://athero.org/ias-inflammation-academy/

3

Reposted by Federica Fogacci

Mineralys Therapeutics @mineralystx.com · Jun 30

Detailed results from the pivotal P3 Launch-HTN trial were published today in @jama.com, reinforcing lorundrostat’s efficacy in a real-world setting.

Read our press release to learn more: ir.mineralystx.com/news-events/...

#BloodPressure #Cardiology #Cardiosky #MLYS

PRESS RELEASE: Mineralys Therapeutics Announces Journal of the American Medical Association (JAMA) Publication of Pivotal Phase 3 Launch-HTN Trial for Lorundrostat

2 3

Federica Fogacci @federicafogacci.bsky.social · Jun 17

Too many children w/ HeFH go undiagnosed. RCPCH has launched 2 🆓 online modules to help paediatricians & HCPs better spot and support them. Let’s close the gap in care #EASSoMe @eassociety.bsky.social
📚 Learn more & take action 👉 learning.rcpch.ac.uk/courses/mana...

*NEW* Management of Heterozygous Familial Hypercholesterolaemia in Children and Young People – RCPCH LearningVisualV1 - ArrowVisualV1 - SearchVisualV1 - CrossVisualV1 - Home VisualV1 - CrossVisualV1 -...

learning.rcpch.ac.uk

1 1

Federica Fogacci @federicafogacci.bsky.social · Jun 1

🎤 First time speaking at #RiminiWellness — I shared some insights on non-pharmacological strategies for managing dyslipidemia. Thanks for the invitation and the audience’s practical questions! Science & wellness grow stronger together #RW25 #CvPrev

1

Reposted by Federica Fogacci

Atanas G. Atanasov @atanas-g-atanasov.bsky.social · May 30

🚨 Heart disease kills 20M+ yearly. Most prevention? Still stuck in the past.

Meet ILEP-SMILE: the 360° strategy tackling not just diet & exercise, but much more!

This isn’t a guideline. It’s a global call to action! 🫀🌍

🔗 www.archivesofmedicalscience.com/A-360-Perspe...

🌐 #INPST #PublicHealth

1 8 14

Federica Fogacci @federicafogacci.bsky.social · May 29

Had the pleasure of delivering a talk at the ANCE Interprovincial Congress on CV prevention & dyslipidemia management in low-risk patients. Empowering 👫 today means healthier tomorrows—for them and the healthcare system. Grateful for the warm welcome! #EASSoMe @eassociety.bsky.social

2 5

Federica Fogacci @federicafogacci.bsky.social · May 21

Great to have Prof. Jung Hyun Choi with us in Bologna during her journey from South Korea to Milan for the ESH Annual Congress. A meaningful exchange ahead of #ESH2025 — and a perfect occasion to let her try tagliatelle al ragù! 🇮🇹🍝 @afgciceromd.bsky.social @unibo.bsky.social

2

Reposted by Federica Fogacci

stefano-romeo.bsky.social @stefano-romeo.bsky.social · May 17

Novel staging system for systemic metabolic disorders! With actionable treatment

Federica Fogacci @federicafogacci.bsky.social · May 12

The brand-new EAS Consensus is here—offering a game-changing, clinically actionable roadmap to tackle met disorders linked to obesity. Time to move from treating symptoms to a full-body, root-cause approach
@eassociety.bsky.social @cibiocm.bsky.social #EASSoMe

4 3

Federica Fogacci @federicafogacci.bsky.social · May 12

Step zero before lifestyle changes, meds, or surgery? Read the 🆕 EAS Consensus!
🔗https://doi.org/10.1093/eurheartj/ehaf314
Because being clueless isn’t a treatment strategy 😎
#EASSoMe @eassociety.bsky.social @cibiocm.bsky.social

Federica Fogacci @federicafogacci.bsky.social · May 12

How do we act?
1⃣ Start w/ lifestyle changes—always the foundation
2⃣ Add the right medications when needed
3⃣ In severe cases, consider surgery
It’s not one-size-fits-all: treatment must match the stage and the organs involved #EASSoMe @eassociety.bsky.social

1 1

Federica Fogacci @federicafogacci.bsky.social · May 12

How do we act?
1⃣ Start w/ lifestyle changes—always the foundation
2⃣ Add the right medications when needed
3⃣ In severe cases, consider surgery
It’s not one-size-fits-all: treatment must match the stage and the organs involved #EASSoMe @eassociety.bsky.social

1 2

Federica Fogacci @federicafogacci.bsky.social · May 12

Excess fat can silently damage your liver, 🫀, kidneys, pancreas—not just 📈 your weight.
That’s why early, multi-organ screening is key. Catch risks before they turn into disease - because progression to later stages means a much higher risk of death ⚠️ @eassociety.bsky.social #EASSoMe

1 1 2

Federica Fogacci @federicafogacci.bsky.social · May 12

📊 Shocking stat: Over 75% of people in the UK Biobank show early signs of systemic metabolic disorders. The new @eassociety.bsky.social staging system (Stage 1–3) helps detect risks early—so we can act before it’s too late. Prevention starts now 🙌 #EASSoMe @cibiocm.bsky.social

1 1 1

Federica Fogacci @federicafogacci.bsky.social · May 12

The brand-new EAS Consensus is here—offering a game-changing, clinically actionable roadmap to tackle met disorders linked to obesity. Time to move from treating symptoms to a full-body, root-cause approach
@eassociety.bsky.social @cibiocm.bsky.social #EASSoMe

1 2 4

Federica Fogacci @federicafogacci.bsky.social · May 8

#MyEAS2025 The live discussion of my case on statin intolerance at #EASCongress2025 was truly exciting! The EAS Stage was packed—much more than the photo shows—and the audience was incredibly engaged. Big thanks to everyone who joined for this rewarding discussion! @eassociety.bsky.social

1 4

Federica Fogacci @federicafogacci.bsky.social · May 8

#MyEAS2025 Honored to join as a panelist at #EASCongress2025 in a session on the power of SoMe in science & networking. Sharing how these platforms launched my journey into ath was truly exciting—and I hope it inspires other early-career researchers! @eassociety.bsky.social @katioorni.bsky.social

2 4

Federica Fogacci @federicafogacci.bsky.social · May 8

💡 Key takeaway in one line! #EASCongress2025 #MyEAS2025 @eassociety.bsky.social
Excited to share the latest breakthroughs in lipid research and clinical practice. Here’s a quick snapshot of yesterday's late-breaking findings 👇

2 2

Federica Fogacci @federicafogacci.bsky.social · May 8

The BROADWAY study results are out now in @nejm.org, published simultaneously with their presentation at #EASCongress2025 🙌 So if you missed Prof. Nicholls' talk—you can catch up here www.nejm.org/doi/full/10....
#EASCongress2025 #MyEAS2025 @maciejbanach.bsky.social @eassociety.bsky.social

3 2

Federica Fogacci @federicafogacci.bsky.social · May 8

Obicetrapib was well tolerated in the BROADWAY study. Long-term effects on CV outcomes will be evaluated in the ongoing PREVAIL trial—but current results suggest it holds considerable promise for improving lipid control in high CV risk patients #EASCongress2025 #MyEAS2025 @eassociety.bsky.social

1 1

Federica Fogacci @federicafogacci.bsky.social · May 8

BROADWAY Study: Additionally, obicetrapib led to a placebo-adj 33.5% reduction in Lp(a), independent of its effects on other lipid parameters and HDL-C increase. The broader lipid effects are also very encouraging #EASCongress2025 #MyEAS2025 @eassociety.bsky.social

1 1

Federica Fogacci @federicafogacci.bsky.social · May 8

BROADWAY study: Obicetrapib, added to maximally tolerated LLT in high-risk CV patients, reduced placebo-adjusted LDL-C by 32.6% at day 84 and 24% at day 365, with 51% of patients reaching LDL-C <55 mg/dL #EASCongress2025 #MyEAS2025 @eassociety.bsky.social

1 1

Federica Fogacci @federicafogacci.bsky.social · May 8

The results of the TANDEM trial have been published in @thelancet.bsky.social , simultaneously with their presentation at the #EASCongress2025! Read the full article here: doi.org/10.1016/S014...
@erinmichos.bsky.social @eassociety.bsky.social #MyEAS2025

1 1

Federica Fogacci @federicafogacci.bsky.social · May 8

While the TANDEM trial has limitations—short follow-up, mainly White participants, and no systematic CV event tracking—if approved, the fixed-dose combo could still offer a valuable new oral option for lowering LDL-C in patients on maximally tolerated LLT #EASCongress2025 @eassociety.bsky.social

1 1

Federica Fogacci @federicafogacci.bsky.social · May 8

Beyond LDL-C, the TANDEM trial showed very encouraging results on ApoB and a high proportion of patients reaching lipid targets. The fixed-dose combo was also well tolerated #EASCongress2025 #MyEAS2025 @eassociety.bsky.social

1 1